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Mesenchymal stem/stromal cells (MSCs) have been widely studied in the field of
regenerative medicine for applications in the treatment of several disease settings.
The therapeutic potential of MSCs has been evaluated in studies in vitro and in vivo,
especially based on their anti-inflammatory and pro-regenerative action, through the
secretion of soluble mediators. In many cases, however, insufficient engraftment and
limited beneficial effects of MSCs indicate the need of approaches to enhance their
survival, migration and therapeutic potential. Genetic engineering emerges as a means
to induce the expression of different proteins and soluble factors with a wide range
of applications, such as growth factors, cytokines, chemokines, transcription factors,
enzymes and microRNAs. Distinct strategies have been applied to induce genetic
modifications with the goal to enhance the potential of MCSs. This review aims to
contribute to the update of the different genetically engineered tools employed for MSCs
modification, as well as the factors investigated in different fields in which genetically
engineered MSCs have been tested.
Keywords: mesenchymal stem/stromal cells, genetic engineering, regenerative medicine, cell therapy, gene
therapy
INTRODUCTION
In the field of stem cell therapy, mesenchymal stem/stromal cells (MSCs) have been widely used in a
large number of in vitro and in vivo studies, as well as in approximately 1000 clinical trials. These are
multipotent stem cells that must meet minimum criteria, such as plastic adherence, expression of
specific surface markers and the ability to differentiate in adipocytes, chondrocytes and osteocytes
(Dominici et al., 2006). Compared to other stem cells, such as embryonic and induced pluripotent
stem cells, the use of MSCs has the advantage of being considered safer, regarding the possibility
of tumor formation. Additionally, these cells are easier to obtain from different autologous or
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allogeneic sources (Kim and Park, 2017). Moreover, MSCs
have the capacity to secrete a repertoire of factors with
immunomodulatory and anti-apoptotic potential, as well as
factors associated to angiogenesis and tissue regeneration
(Murphy et al., 2013).
While in numerous studies the therapeutic effects of MSCs
have been shown, in others the transplantation of MSCs did not
lead to the desired effect, as evaluated in different disease models
(Meyer et al., 2006; Huang B. et al., 2012; Sajic et al., 2012). Some
studies have shown that transplanted MSCs presented a poor
survival rate and proliferation (Shi and Li, 2008; Park J.S. et al.,
2015; Li et al., 2016; Silva et al., 2018c; Zhao et al., 2019), possibly
due to the hostile microenvironment of lesioned tissues, which
could lead to nutrient deprivation and cell death (Moya et al.,
2018). Moreover, partial beneficial effects may be enhanced by
expression of specific factors capable of promoting desired effects
in the target disease setting. Therefore, approaches aiming to
enhance the efficacy of MSC transplantation are needed in order
to achieve the suitable results.
Genetic engineering of MSCs has been studied in the past
years with the purpose of enhancing the therapeutic potential
of these cells and improving the outcomes after transplantation.
This has been achieved using non-viral or viral vectors to induce
the expression of different factors, depending on the desired
results, such as increasing their survival and proliferation rate
and improving their pro-regenerative capacity (Sage et al., 2016;
Foppiani et al., 2019). In this review, we discuss the current
methods employed in the generation of genetically modified
MSCs and the results obtained with the expression of different
factors and the main disease settings in which this modality of
cell and gene therapy has been investigated. Table 1 summarizes
the modification agents, cell source, genetic engineering method
and applications of diverse studies described in this review.
MSC AS A CELL TARGET FOR GENETIC
MODIFICATION AND GENE THERAPY
Several genetic engineering methods to modify the MSCs gene
expression profile have been described, as seen in Table 2. These
techniques can be classified as those using viral vectors or non-
viral methods. Replication-deficient viruses are the most used
gene transfer tools, mainly due to their high efficiency in DNA
transfer when compared to non-viral methods. However, the use
of viral vectors in the clinical practice has been limited by the
high cost of cell line production and the possibility of adverse
immunological reactions, or even the occurrence of insertional
mutagenesis, which may lead to the activation of oncogenes (Park
J.S. et al., 2015).
Non-viral methods, on the other hand, can be manufactured
on a large scale and have low immunogenicity. Currently,
the genetic modification of MSCs using non-viral vectors can
be performed by physical or chemical methods. The physical
methods used in MSCs include electroporation, nucleofection
and sonoporation (Otani et al., 2009; Baraniak and Mcdevitt,
2010; Cantinieaux et al., 2013). Chemical methods use lipidic
agents, polymers and inorganic nanoparticles (Uchimura et al.,
2007; Park et al., 2010). Although the use of non-viral vectors
has some advantages for the process of genetic modification of
MSCs compared to viral vectors, the impairment of cell viability,
low efficiency and transient expression of transgenes make these
methods less used in the clinical practice (Marofi et al., 2017).
Viral vectors are the most used tool in the MSC genetic
modification protocols, and it has been demonstrated that the
high efficiency of viral transduction in these cells (approximately
90%) does not affect their immunophenotypic characteristics,
as well as their potential for cell differentiation and secretion
of bioactive molecules, which are preserved after genetic
modification (Delcayre et al., 2005; Biancone et al., 2012).
In addition, viral transduction ensures stable and long-
term transcription of the gene of interest and, consequently,
a greater efficiency compared to other methods that do
not use viral vectors for genetic modification of MSCs
(Sage et al., 2016). Currently, there is extensive clinical
experience with several types of vectors that include mainly
vaccinia, measles, vesicular stomatitis virus (VSV), polio,
reovirus, adenovirus, lentivirus, retrovirus, adeno-associated
virus (AAV), and herpes virus simplex (HSV). Among those,
the most predominant vectors used for cell transduction
and transplantation are the lenti- and retroviral vectors.
Beyond those applications, AAV vectors have been used as
favored vehicle for direct gene delivery to specific tissues
(Finer and Glorioso, 2017).
Adenoviral vectors do not integrate into the host genome
and can transduce both dividing and quiescent cells with
high efficiency. Obtaining high titers of the recombinant
vectors is relatively easy with little cytotoxic effect on the
packaging cells (Vemula and Mittal, 2010). However, the high
immunogenicity and transient expression of the transgene
limits its application in clinical practice (Somia and Verma,
2000). Adeno-associated viruses, on the other hand, have no
viral gene in its recombinant form used for gene therapy,
a characteristic that contributes to a low immunogenicity
and pathogenicity. Also, they are dependent on co-infection
with other viruses, mainly adenoviruses, in order to replicate.
Recombinant adeno-associated viruses episomal DNA is
unable to integrate in the host genome, therefore reducing
the consistency of transgene expression along the time
in proliferating cells (Sage et al., 2016; Naso et al., 2017).
However, a limiting factor for the use of AAVs is the action
of neutralizing antibodies present in a large part of the
population, which drastically reduces their effectiveness in vivo
(Nayak and Herzog, 2010).
Retroviruses are RNA viruses made up of three essential genes:
gag, pol and env, which encode the structural protein, reverse
transcriptase / integrase and glycoprotein of the viral envelope,
respectively. These genes are arranged in separate plasmids and
separately for the packaging cells in order to avoid recombination
or generation of retroviruses competent for viral replication.
Obtaining high viral titers is relatively easy using these vectors;
however, the biggest limitation of retroviral vectors is their
inability to transduce quiescent cells. Lentiviruses, however, have
the property of transducing dividing and quiescent cells (Lewis
et al., 1992; Vargas et al., 2016). Currently, lentiviral vectors are
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TABLE 1 | Genetic modifications in MSCs and disease models tested.
Factor overexpressed MSC source Method Disease References
Akt Mouse bone marrow Retrovirus Myocardial infarction Noiseux et al., 2006
Rabbit amniotic fluid Lentivirus Heart ischemia-reperfusion
injury
Wang et al., 2016
Human umbilical cord Adenovirus Acute myocardial infarction Ma et al., 2017
Rat bone marrow Retrovirus Myocardial infarction Gnecchi et al., 2006, 2009
Akt and angiopoietin-1 (Ang-1) Rat bone marrow Adenovirus Infarcted heart Jiang et al., 2006
Akt and Wnt11 Rat bone marrow AAV Hypoxia/reoxygenation-induced
cardiomyocyte apoptosis
Chen B. et al., 2018
Angiogenin Yorkshire pig bone
marrow
Adenovirus Myocardial chronic ischemic Huang et al., 2006




Mei et al., 2007
Rat bone marrow Lentivirus Phosgene-induced acute lung
injury
Shao et al., 2018
Angiotensin II type 2 receptor Human bone marrow Lentivirus LPS-induced acute lung injury Xu et al., 2018
Angiotensin-converting enzyme 2 (ACE2) Mouse bone marrow Lentivirus Acute lung injury He et al., 2015
Arginine decarboxylase Human adipose tissue Retrovirus Spinal cord injury Park Y.M. et al., 2015
ATP7B Human bone marrow Retrovirus Wilson’s disease Sauer et al., 2010
Basic fibroblast growth factor (bFGF) Human bone marrow Lentivirus Angiogenesis Fierro et al., 2011
Rat bone marrow Lentivirus Ischemic disease Zhang J.C. et al., 2014
B-cell lymphoma protein 2 (BCL-2) Rat bone marrow AAV Liver cirrhosis Jin et al., 2016




Neurological injury and disease Lim et al., 2011
Human bone marrow Lentivirus Neuronal degeneration Scheper et al., 2019
Rat bone marrow Adenovirus Spinal cord injury Zhao et al., 2013
Rat bone marrow Adenovirus Neonatal stroke Van Velthoven et al., 2013
Rat bone marrow Lentivirus Ischemia Zhou et al., 2017
C1q/tumor necrosis factor-related protein-3
(CTRP3)
Mouse bone marrow Lentivirus Myocardial infarction Zhang Z. et al., 2019
C-C chemokine receptor type 2 (CCR2) Human bone marrow Lentivirus Ischemic stroke Zhang Y. et al., 2018
C-C chemokine receptor type 1 CCR1 Mouse bone marrow Retrovirus Injured myocardium Huang et al., 2010
Cellular repressor of E1A-stimulated genes
(CREG)
Rat bone marrow Adenovirus Myocardial infarction Deng et al., 2010
Cerebral dopamine neurotrophic factor (CDNF) Rat bone marrow Lentivirus Spinal cord injury Zhao et al., 2014
Ciliary neurotrophic factor (CNTF) Rat bone marrow Plasmid
transfection
Traumatic injury to the central
nervous system
Abbaszadeh et al., 2015
c-MYC Mouse bone marrow Retrovirus Osteosarcoma Shimizu et al., 2010
Csx/Nkx2.5 and GATA4 Mouse bone marrow Retrovirus Stochastic cardiomyogenic fate Yamada et al., 2007
Mouse bone marrow Retrovirus Myocardial infarction Gao et al., 2011
CXC chemokine receptor 4 (CXCR4) Human umbilical cord Lentivirus Radiation- induced lung injury Zhang C. et al., 2019
Mouse bone marrow Retrovirus Breast cancer Kalimuthu et al., 2017
Mouse bone marrow Lentivirus Inflammatory bowel and cancer Zheng et al., 2019
Rat bone marrow Retrovirus Myocardial infarction Cheng et al., 2008
Rat bone marrow Adenovirus Ischemic heart injury Wu S. Z. et al., 2017
Rat bone marrow Lentivirus Myocardial infarction Kang et al., 2015
Mouse bone marrow Lentivirus Acute kidney injury Liu et al., 2013
Rat bone marrow Adenovirus Liver regeneration Du et al., 2013
Rat bone marrow Lentivirus Myocardial neovascularization Liang et al., 2012
Mouse bone marrow Adenovirus Myocardial infarction Huang Z. Y. et al., 2012
Rat bone marrow Adenovirus Myocardial infarction Zhang et al., 2008
CXC chemokine receptor 7 (CXCR7) Rat bone marrow Lentivirus Acute lung injury Shao et al., 2019
Cytosine deaminase (CD) and Herpes simplex
virus thymidine kinase (HSV-tk)
Human umbilical cord
blood
Lentivirus Ovarian cancer Jiang et al., 2014
(Continued)
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 August 2020 | Volume 8 | Article 737
fcell-08-00737 August 20, 2020 Time: 20:10 # 4
Damasceno et al. Genetically Engineered MSCs in Regenerative Medicine
TABLE 1 | Continued
Factor overexpressed MSC source Method Disease References
Drosophila mothers against decapentaplegic 7
(Smad7)
Rat bone marrow Lentivirus Hepatic fibrosis Wu S. P. et al., 2017
Endothelial nitric oxide synthase (eNOS) Rat bone marrow Adenovirus Endothelial dysfunction Kanki-Horimoto et al., 2006
Mouse bone marrow Adenovirus Myocardial Infarction Chen L. et al., 2017
Ephrin-B2 Human bone marrow Plasmid
transfection
Ischemic tissues Duffy et al., 2010
Erythropoietin (EPO) Mouse bone marrow Retrovirus Myocardial infarction Copland et al., 2008
Mouse bone marrow Retrovirus Cancer immunotherapy Campeau et al., 2009
Extracellular regulating kinase 1/2 (ERK1/2) Rat bone marrow Lentivirus Ischemic stroke Gao et al., 2019
Fibroblast growth factor 21 (FGF21) Mouse bone marrow Lentivirus Traumatic brain injury Shahror et al., 2019
Fibroblast growth factor 4 (FGF4) Rat bone marrow Lentivirus Liver cirrhosis Wang et al., 2015
Follistatin-like 1 (Fstl1) Mouse bone marrow Lentivirus Myocardial infarction Shen et al., 2019
Forkhead box protein (Foxa2) Human adipose tissue Plasmid
transfection
Acute liver injury Chae et al., 2019
Rat bone marrow Plasmid
transfection
Hepatic diseases Cho J.W. et al., 2012
GATA-4 Mouse bone marrow Lentivirus Myocardial infarction He et al., 2019
Rat bone marrow Retrovirus Myocardial ischemia Yu B. et al., 2016
Rat bone marrow Retrovirus Heart ischemic injury Li et al., 2014
Glial-derived neurotrophic factor (GDNF) Human adipose Lentivirus Renal interstitial fibrosis Wang Z. et al., 2019
Rat bone marrow Plasmid
transfection
Neurodegenerative diseases Noori-Zadeh et al., 2014
Human bone marrow Adenovirus Nephrotoxic serum nephritis
(NSN)
Huang Z. Y. et al., 2012
Rat bone marrow Adenovirus Intracerebral hemorrhage (ICH) Yang et al., 2011
Glucocorticoid-induced tumor necrosis
factor–related receptor (GITR)
Human bone marrow Plasmid
transfection
Small cell lung cancer Kopru et al., 2018
Glycogen synthase kinase-3β (GSK-3β) Mouse bone marrow Adenovirus Myocardial infarction Cho et al., 2011
Granulocyte chemotactic protein (GCP)-2 Human adipose tissue Lentivirus Myocardial infarction Kim et al., 2012
Granulocyte-colony stimulating factor (G-CSF) Mouse bone marrow Lentivirus Chagas disease
cardiomyopathy
Silva et al., 2018b
Heme oxygenase-1 (HO-1) Mouse adipose tissue Plasmid
transfection
Heart ischemic injury Preda et al., 2014
Rat bone marrow Lentivirus Acute lung injury Chen X. et al., 2018
Dog adipose tissue Lentivirus Spinal cord injury Lee et al., 2017
Human embryonic
stem cell
Lentivirus Myocardial infarction Kearns-Jonker et al., 2012
Rabbit adipose tissue Adenovirus Myocardial infarction Yang et al., 2012
Hepatocyte growth factor (HGF) Human bone marrow Retrovirus Bladder outlet obstruction Song et al., 2012
Rat bone marrow Adenovirus Hepatocirrhosis Zhang Y. et al., 2018
Human umbilical cord Lentivirus Myocardial infarction Zhao et al., 2016
Human bone marrow Adenovirus Liver fibrosis Lai et al., 2015
Human umbilical cord Adenovirus Injured sinonasal mucosa Li et al., 2015
Rat bone marrow Lentivirus Liver damage caused by
radiotherapy
Zhang J. et al., 2014





Liver fibrosis Seo et al., 2014
Rat bone marrow Adenovirus Pulmonary arterial hypertension Guo et al., 2013
Human bone marrow Lentivirus Spinal cord injury Jeong et al., 2012
Rat bone marrow Adenovirus Post-ischemic heart failure Guo et al., 2008
Pig adipose tissue Lentivirus Intramyocardial transplant Gómez-Mauricio et al., 2016
Hepatocyte nuclear factor 4α (HNF4α) Human umbilical cord Lentivirus Hepatocellular carcinogenesis
(HCC)
Wu et al., 2016
Mouse bone marrow Adenovirus Liver cirrhosis Ye et al., 2019
Human a1-antitrypsin (hAAT) Mouse adipose tissue Lentivirus Disorders of liver metabolism Di Rocco et al., 2012
(Continued)
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TABLE 1 | Continued
Factor overexpressed MSC source Method Disease References
Human elastin Rat bone marrow Adenovirus Myocardial infarction Li et al., 2012
Human N-cadherin Human umbilical cord
blood
Lentivirus Myocardial infarction Lee et al., 2012
Hypoxia inducible factor (HIF)-1α. Human bone marrow Lentivirus Angiogenesis Razban et al., 2012
Rat bone marrow Adenovirus Ischemic cerebrovascular
disease
Yang et al., 2014
Sheep bone marrow Plasmid
transfection
Acute myocardial infarction Hnatiuk et al., 2016
IL-1Ra Rats amniotic fluid Lentivirus Fulminant hepatic failure Zheng et al., 2012
IL-33 Rat bone marrow Lentivirus Myocardial infarction Chen Y. et al., 2017
IL-4 Human adipose tissue Lentivirus Multiple sclerosis Payne et al., 2012
Insulin growth factor like-I (IGF-I) Rat bone marrow Adenovirus Myocardial infarction Haider et al., 2008
Mouse bone marrow Retrovirus Renal failure-induced anemia Kucic et al., 2008
Pig adipose tissue Lentivirus Intramyocardial transplant Gómez-Mauricio et al., 2016
Mouse bone marrow Retrovirus Spinal cord injury Allahdadi et al., 2019




Silva et al., 2018a
Mouse bone marrow Adenovirus Cirrhosis Fiore et al., 2015
Integrin linked kinase (ILK) Mini-pig bone marrow Adenovirus Myocardial infarction Mao Q. et al., 2014
Rats bone marrow Adenovirus Myocardial infarction Mao et al., 2013
Integrin α4 Rat bone marrow Lentivirus Cerebral Embolism Cui et al., 2017
Intercellular Adhesion Molecule 1 (ICAM-1) Mouse compact bone Plasmid
transfection
Inflammatory bowel disease Li et al., 2019
Interferon-beta (IFN-β) Dog adipose tissue Lentivirus Melanoma Han et al., 2015
Mouse bone marrow Lentivirus Breast cancer Ling et al., 2010
Interleukin-10 Mouse bone marrow CRISPRa system Myocardial infarction Meng et al., 2019
Rat bone marrow Lentivirus Traumatic brain injury Maiti et al., 2019
Human amniotic fluid Adenovirus Liver fibrosis Choi et al., 2019
Mouse bone marrow Retrovirus Acute lung injury Wang et al., 2018
Human bone marrow AAV Acute Ischemic Stroke Nakajima et al., 2017
Rat bone marrow Adenovirus Myocardial infarction Meng et al., 2017
Klotho Mouse bone marrow Adenovirus Acute kidney injury Zhang F. et al., 2018
Large Tumor Suppressor gene 2 (LATS2) Mouse bone marrow Lentivirus Acute respiratory distress
syndrome
Dong and Li, 2019
Leptin Human bone marrow Lentivirus Myocardial infarction Yang et al., 2018
LIM-homeobox transcription factor islet-1 (ISL1) Human bone marrow Lentivirus Myocardial infarction Xiang et al., 2018
Lipocalin2 (Lcn2) Rats bone marrow Plasmid
transfection
Kidney injury Halabian et al., 2014
Liver X receptor-α (LXRα) Mouse bone marrow Retrovirus Pathophysiology of the
renin-angiotensin system
Matsushita et al., 2010
Mammalian achaete-scute homologue-1
(Mash1)
Rat bone marrow Lentivirus Neurodegenerative disorders Wang K. et al., 2013
MCT4 Mouse bone marrow Retrovirus Myocardial ischemia Saraswati et al., 2015
miR-1 Mouse bone marrow Lentivirus Myocardial infarction Huang et al., 2013b
miR-101-3p Human bone marrow Lentivirus Oral cancer Xie et al., 2019
miR-124 Rat bone marrow Lentivirus Spinal cord injury Zou et al., 2014
miR-126 Mouse bone marrow Lentivirus Ischemic angiogenesis Huang et al., 2013a
miR-133 Rat bone marrow Lentivirus Acute myocardial infarction Chen L. et al., 2017
miR-133b Rat bone marrow Lentivirus Stroke Xin et al., 2017
miR-16−5p Human bone marrow Plasmid
transfection
Colorectal cancer Xu et al., 2019
miR-199a Human bone marrow Plasmid
transfection
Glioma Yu et al., 2019
miR-199a-3p Human bone marrow miRNA transfection Renal ischemia/reperfusion
injury
Zhu et al., 2019
(Continued)
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 August 2020 | Volume 8 | Article 737
fcell-08-00737 August 20, 2020 Time: 20:10 # 6
Damasceno et al. Genetically Engineered MSCs in Regenerative Medicine
TABLE 1 | Continued
Factor overexpressed MSC source Method Disease References
miR-211 Rat and human bone
marrows
Lentivirus Adverse post-MI remodeling Hu et al., 2016
miR-23a Rat bone marrow Lentivirus Myocardial infarction Mao J. et al., 2014
miR-30b-3p Mouse bone marrow Lentivirus Acute lung injury Yi et al., 2019
miR-34a Human bone marrow Lentivirus Glioblastoma Wang B. et al., 2019
miR-705 Mouse bone marrow Lentivirus Ischemic brain injury Ji et al., 2017
miR-let-7d or miR-154 Human bone marrow Lentivirus Lung injury Huleihel et al., 2017




Wei et al., 2019
miRNA-21 Rat bone marrow Lentivirus Intracerebral hemorrhage Zhang H. et al., 2018
miRNA-21 Rat bone marrow Lentivirus Myocardial damage Zeng et al., 2017
miRNA-25 Rat bone marrow Lentivirus Transient spinal cord ischemia Zhao et al., 2018
as-miR-937 Mouse bone marrow Alzheimer’s Disease Liu et al., 2015
Monocyte chemoattractant protein-induced
protein 1 (MCPIP1)
Mouse bone marrow Retrovirus Myocardial repair Labedz-Maslowska et al.,
2015
Neuregulin 1 (NRG1) Human adipose tissue Adenovirus Cerebral ischemia Ryu et al., 2019
Neuregulin 4 (Nrg4) Mouse adipose tissue Lentivirus Insulin resistance and hepatic
steatosis
Wang W. et al., 2019
Neurotrophin-3 (NT-3) Rat bone marrow Plasmid
transfection
Parkinson disease Moradian et al., 2017
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) Human amniotic fluid Lentivirus Acute lung injury Zhang et al., 2017
Oct4 and Sox2 Human adipose tissue Plasmid
transfection
Liver injury Han et al., 2014
p130 and E2F4 Mouse bone marrow Lentivirus Acute respiratory distress
syndrome
Zhang X. et al., 2019
PARKIN Human Wharton’s jelly Plasmid
transfection
Parkinson’s disease Bonilla-Porras et al., 2018
Periostin Rat bone marrow Lentivirus Myocardial infarction Cho Y.H. et al., 2012
Pigment epithelial-derived factor (PEDF) Human bone marrow Lentivirus Hepatocellular carcinoma Gao et al., 2010






Huang Y. et al., 2018
Mouse bone marrow AAV Glioma Wang Q. et al., 2013
Receptor activity-modifying protein 1 (RAMP1) Rabbit bone marrow Adenovirus Carotid angioplasty and
myocardial infarction
Shi et al., 2014
Receptor tyrosine kinase-like orphan receptor 2
(ROR2)
Mouse bone marrow Lentivirus Acute respiratory distress
syndrome (ARDS)
Cai et al., 2016
Sirtuin 1 (Sirt 1) Mouse bone marrow Adenovirus Prostate cancer Yu Y. et al., 2016
Sonic Hedgehog (Shh) Mouse bone marrow Lentivirus Inflamed stomach Donnelly et al., 2014
Rat bone marrow Lentivirus Spinal cord injury Jia et al., 2014
SRC3-specific short hairpin RNA (sh-SRC3) Human bone marrow Lentivirus Multiple myeloma Ji et al., 2017
sST2 Human adipose tissue Lentivirus Occupational asthma Martínez-González et al.,
2014




Stromal cell derived factor-1 (SDF-1) Rat bone marrow Lentivirus Acute myocardial infarction Unzek et al., 2007
Mouse bone marrow Lentivirus Post-acute myocardial
infarction





Myocardial infarction Gong et al., 2019
Rat and human bone
marrows
Retrovirus Spinal cord injuries Stewart et al., 2017
Telomerase (TERT) and myocardin (MYOCD) Mouse adipose tissue Lentivirus Ischemic cardiovascular
diseases
Madonna et al., 2019
Thioredoxin-1 (Trx-1) Human umbilical cord Adenovirus Acute radiation injury (ARI) Hu et al., 2013
(Continued)
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TABLE 1 | Continued
Factor overexpressed MSC source Method Disease References
Tissue matrix metalloproteinase inhibitor 2
(TIMP2)
Human umbilical cord Lentivirus Myocardial infarction Ni et al., 2019
TNF-related apoptosis-inducing ligand (TRAIL) Human bone marrow Lentivirus Non-small cell lung cancer Xia et al., 2013
Human adipose tissue Plasmid
transfection
Glioblastoma multiforme Jiang et al., 2016
Human adipose tissue Lentivirus Pancreatic ductal
adenocarcinoma
Spano et al., 2019
Human bone marrow Lentivirus Colorectal carcinoma Mueller et al., 2011
Human bone marrow Lentivirus Metastatic lung tumors Loebinger et al., 2009
Human bone marrow Lentivirus Cancer cell lines Yuan et al., 2017
Transforming growth factor (TGF)β1 Human bone marrow Lentivirus Angiogenesis Fierro et al., 2011
Rat bone marrow Lentivirus Renal ischemia/reperfusion
injury
Cai et al., 2019
Tropomyosin receptor kinase A (TrkA) Rat bone marrow Lentivirus Peripheral nerve injury Zheng et al., 2017
Tumor necrosis factor α (TNF α) Human adipose tissue Retrovirus Lung metastases Tyciakova et al., 2017
Tyrosine kinase C (TrkC) Rat bone marrow Adenovirus Spinal cord injury Ding et al., 2013
Rat bone marrow Adenovirus Demyelinated spinal cord Ding et al., 2015
Urokinase plasminogen activator Human umbilical cord
blood
Adenovirus Tumor tropism Pulukuri et al., 2010
Vascular endothelial growth factor (VEGF) Human bone marrow Lentivirus Peripheral nerve injury Man et al., 2016
Sheep bone marrow Plasmid
transfection
Myocardial infarction Locatelli et al., 2015
Mouse bone marrow Plasmid
transfection
Alzheimer’s disease Garcia et al., 2014
Rat bone marrow Lentivirus Cardiac arrest Zhou et al., 2017
Mouse bone marrow Adenovirus Heart infarction Wang et al., 2006
Wnt11 Rat bone marrow Retrovirus Cardiac ischemic Injury Zuo et al., 2012
β-catenin Mouse bone marrow Lentivirus Acute respiratory distress
syndrome (ARDS)
Cai et al., 2015
the most used in gene therapy, whether in preclinical or clinical
studies, as they guarantee high process efficiency, as shown by
the increased number of phase I clinical studies evaluating the
safety of gene therapies using lentiviruses conducted in recent
years (Milone and O’Doherty, 2018).
Recently, new genetic modification tools arose in order to
promote insertion, deletion or correction of genes at specific
sites in the genome, and MSCs have been used as a target
for these new modifying tools for applications in different
diseases (Torres et al., 2014; van den Akker et al., 2016; Gerace
et al., 2017; Li et al., 2018; Meng et al., 2019). The site-
specific integration of genes can be achieved using tools such
as Zinc Finger Nuclease (ZFN), Transcription Activator-Like
Effector Nuclease (TALENS) or Clustered Regularly Interspaced
Short Palindromic Repeats (CRISPR/Cas9), which are nucleases
capable of recognizing and direct the integration of genes
in a site-specific manner. These molecular-editing tools can
be further explored to improve safety and efficiency of gene
insertion/expression (Park J.S. et al., 2015).
APPLICATIONS IN CANCER TREATMENT
Cancer is the second leading cause of global death (WHO, 2020),
and conventional chemotherapies have shown poor efficacy for
the treatment of cancer in advanced stages. Cell therapy emerged
in the last years as a promising tool for cancer treatment.
Furthermore, a growing number of cell therapies are being tested
in combination with other therapeutic agents, such as checkpoint
inhibitors (Li et al., 2017; Hu et al., 2018; Cao et al., 2019).
Along the past years, many studies have been focused on
MSCs potential to act as “Trojan horses,” promoting the delivery
of anticancer immunostimulatory agents, such as chemokines
and cytokines, to cancer site due to their tumoral tropism
(Hmadcha et al., 2020). The chemokine receptor 4 (CXCR4)
plays a critical role in MSCs homing and survival to tumor
sites. Overexpression of CXCR4 in adipose tissue (Ad-MSCs)
and bone marrow (BMSCs) MSCs promoted anti-tumor activity
in different studies (Bobis-Wozowicz et al., 2011). In a mouse
model of colitis-associated tumorigenesis, BMSCs transduced
with lentiviral vector carrying either CXCR4 had an enhanced
homing (2-fold) to inflamed intestinal tissues when compared
to control MSCs (Zheng et al., 2019). This higher migratory
and engraftment capacity was also observed in an in vivo breast
cancer mouse model, in which MSCs administered systemically
via the tail vein reached the tumors, even though part of the
cells remained in the lungs. Moreover, the overexpression of
CXCR4 in MSCs increased the accumulation in the tumor
compared to non-CXCR4-overexpressing MSCs (Kalimuthu
et al., 2017). A study using BMSCs genetically modified to express
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TABLE 2 | Genetic engineering methods for MSCs modification.
Genetic engineering methods Advantages Limitations
Retrovirus - Easy manipulation and vector design - Only transduce dividing cells
- Stable and efficient gene transfer - Risk of insertional mutagenesis
- Extensive cell transduction tropism
Lentivirus - Transduce dividing and non-dividing cells - Risk of insertional mutagenesis
- Stable and efficient gene transfer - Size of the therapeutic gene (<10 kb) insert
- High levels of transgene expression
- High titers
Adenovirus - Efficient gene transfer - Transient gene expression
- Large insert capacity - High immunogenicity
Adeno-associated virus - Efficient gene transfer - Small size of the therapeutic gene insert (<5 kb)
- Extensive cell transduction tropism - Low yield (hard to produce)
- Low immunogenicity - Transient gene expression in dividing cells
Non-viral (Liposomes and plasmids) - Low immunogenicity - Low transfection efficiency
- Safe manipulation - Transient gene expression
CRISPR/Cas9, ZFN and TALEN - Precise gene edition (mutation, insertion, replacement,
or deletion)
-Off-target effects risk
- Relative high efficiency - Target sequencing must precede a protospacer adjacent
motif (PAM) (CRISPR/Cas9)
-Not easy to design (ZNF and TALEN)
the CXC receptor 7 (CXCR7), a newly discovered chemokine
ligand 12 (CXCL12) receptor that promotes migration to
tumor, showed an increase in cell migration and proliferation,
which may be attributed to the CXCL12 secreted by MSCs,
thus promoting a positive feedback for CXCL12/CXCR7 axis
(Liu et al., 2018).
Another explored cancer therapy strategy was the genetic
modification of Ad-MSCs to overexpress the cytokine interferon-
beta (IFN-β) in an in vitro model of canine melanoma.
The cytokine family in which IFN-β belongs is known
for their antiviral, immunomodulatory and antiproliferative
effects. This approach was tested as an adjunctive therapy
in order to begin and maintain skin lesion remission caused
by pemphigus foliaceus. Ad-MSCs overexpressing IFN-β was
associated with pro-apoptotic and growth-inhibitory effects on
canine melanoma cells when compared with non-modified MSCs
(Han et al., 2015).
The tumor homing of MSCs has been used to deliver
TNF-related apoptosis-inducing ligand (TRAIL), known by
its anticancer properties. MSCs overexpressing TRAIL (MSC-
TRAIL), when co-cultured with tumor cells, induced a 6-fold
increase in apoptotic cell death when compared to non-modified
MSCs. In addition, these cells were tested in a metastatic lung
mouse model, promoting a tumor free rate of 37.5%, whereas no
animals were tumor-free in the control MSCs group (Loebinger
et al., 2009). Confirmation of the efficacy of MSC-TRAIL in vivo
were shown by Spano et al. (2019), which tested Ad-MSC-TRAIL
in pancreatic cancer, finding a 37% reduction in tumor size in
Ad-MSC-TRAIL group compared to non-modified Ad-MSCs, a
result which was similar to the that found in the group treated
with recombinant TRAIL. Moreover, an increased cytotoxicity
of TRAIL-expressing MSCs compared to control MSCs was also
seen in a lung cancer in vivo model, possibly by enhancing the
apoptosis of CLDN7-negative non-small cell lung cancer cells
(Xia et al., 2013).
The effects of MSCs-derived exosomes, which are secreted
vesicles with an average size of 100 nm originated from the
endosomal compartment (Kalluri and LeBleu, 2020), have also
been explored in the context of cancer therapy (Gao and Jiang,
2018). Exosomes isolated from MSCs overexpressing microRNAs
(MIRs) were also evaluated in different cancer models (Wang B.
et al., 2019; Xu et al., 2019; Chen et al., 2020). Treatment with
BMSCs-derived exosomes overexpressing miR-16-5p in a mouse
model of colorectal cancer (CRC) inhibited invasion, migration
and proliferation of malignant cells, and induced a 4-fold higher
apoptosis rate in vitro compared to control cells (Xu et al., 2019).
Exosomes from BMSCs overexpressing miR-34 were 2-fold more
potent than control MSCs in inducing the inhibition of invasion,
migration, proliferation and tumorigenesis of glioblastoma cells,
in vitro and in vivo (Wang B. et al., 2019). Exosomes from
miR-101-3p and miR-199a-overexpressing BMSCs also inhibited
invasion, migration and proliferation of oral cancer cells (Xie
et al., 2019) and glioma cells (Yu et al., 2019). Furthermore,
inhibition of the tumor progression was also observed in vivo in
a glioma model (Yu et al., 2019).
In a prostate cancer model, administration of BMSCs
overexpressing sirtuin 1 led to a decrease in tumor growth and
an increase in immune inflammatory response associated with
the IFN-γ-induced recruitment and activation of tumoricidal
macrophages when compared to non-modified MSCs (Yu Y.
et al., 2016). The effects of conditioned medium of umbilical
cord-derived MSCs (UC-MSCs) overexpressing hepatocyte
nuclear factor 4α (HNF4α), a transcription factor which acts as a
master regulator of hepatic differentiation and liver metabolism,
has also been evaluated in a mouse model of hepatocellular
carcinogenesis (HCC). UC-MSC-HNF4α suppressed metastasis
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and proliferation of cancer cells when compared to untreated
and control MSCs-treated groups. Furthermore, in an in vitro
assay, MSC-HNF4α reduced approximately 5-fold the migration
and invasion potential of cancer cells compared to controls
(Wu et al., 2016).
APPLICATIONS IN CARDIOVASCULAR
DISEASES
Novel treatments for improving the heart function are of
immense clinical importance, and cell-based therapies show a
great promise (Jadczyk et al., 2017). A variety of cell types,
including MSCs, have been used in strategies for inducing cardiac
regeneration (Madonna et al., 2010). Initially, it was proposed
the differentiation of transplanted MSC into cardiomyocytes
and vessels as the main mechanism underlying their therapeutic
action in cardiovascular diseases (Tomita et al., 1999; Pittenger
and Martin, 2004). However, the number of MSCs-derived
cells has been shown to be too low to contribute to the
functional improvements, and evidence supports the hypothesis
that MSC-mediated paracrine mechanisms play an essential role
in tissue repair (Luo et al., 2019). Among the mechanisms
promoted by MSCs are neovascularization, cytoprotection,
endogenous cardiac regeneration, modulation of inflammatory
and fibrogenic processes, cardiac contractility and cardiac
metabolism (Gnecchi and Cervio, 2013).
Mesenchymal stem/stromal cells have been genetically
modified to express factors that resulted in significant
improvements in cardiac recovery. Several authors selected
factors to be introduced in a gene therapy approach, based
on the putative beneficial effects of MSCs described in infarct
myocardial models, such as growth factors. MSCs overexpressing
vascular endothelial growth factor (VEGF), when delivered by
intramyocardial injection, reduced the infarcted area in 31% and
improved left ventricular function to almost its baseline when
compared with non-transfected MSCs (Locatelli et al., 2015).
In a mouse model of myocardial infarction, transplantation of
umbilical cord-MSCs overexpressing hepatocyte growth factor
(HGF), a pro-regenerative factor, reduced by approximately half
the infarcted area when compared with non-transduced cells, in
addition to significantly increase the survival rate post-transplant
(Zhao et al., 2016). In addition, the pro-survival cytokine
insulin-like growth factor (IGF)-1, when overexpressed by
BMSCs, reduced by approximately 50% the number of apoptotic
myocardial cells post-transplant compared to animals treated
with control MSCs, and increased MSC retention in the tissue in
an experimental model of myocardial infarction (Haider et al.,
2008). Similar results were observed after C1q/tumor necrosis
factor-related protein-3 (CTRP3) and CCR1-modified MSCs
transplant. MSCs overexpressing CTRP3, which is associated
with protective effects after myocardial infarct, had an enhanced
survival and retention 7 days post-transplant, approximately
three times higher when compared to unmodified control cells
(Zhang Z. et al., 2019). Additionally, overexpression of CCR1
increased by∼90% the chemokinesis of MSC in vitro and in vivo,
also increasing by more than 50% the amount of viable MSCs in
the infarcted myocardium area (Huang et al., 2010).
The therapeutic effects of MSCs overexpression growth
factors were also studied in a mouse model of cardiomyopathy
induced by chronic infection with Trypanosoma cruzi, the
causative agent of Chagas disease. Administration of genetically
modified mesenchymal cells overexpressing granulocyte colony-
stimulating factor (G-CSF) were about 2-fold more potent in
reducing the number of inflammatory cells and the percentage
of fibrosis than control MSCs, acting by increasing the number
of myeloid-derived suppressor cells and T regulatory cells (Silva
et al., 2018b). In contrast, no increase in anti-inflammatory
or antifibrotic activity was seen after transplantation of IGF-
overexpressing MSCs in T. cruzi-infected animals. However,
an increased pro-regenerative activity in skeletal muscle was
observed after MSCs-IGF-1 transplantation, compared to control
MSCs, increasing the number of myofibers similar to that of
uninfected mice (Silva et al., 2018a).
The overexpression of the regulators of cardiogenesis Csx/Nkx
2.5 and GATA-4 was also investigated in a myocardial infarct
model. Genetically modified MSCs overexpressing these factors
increased the cardiac function by inducing pro-angiogenic
effects, significantly increasing microvessel density in the
peri-infarct regions and reducing cell loss by apoptosis by
approximately 10% compared to animals treated with control
MSCs (Gao et al., 2011; He et al., 2019).
In addition to their pro-angiogenic effects, the cellular benefits
of MSCs may also be mediated by activating the survival
kinase pathways, including Akt activation, in cardiomyocytes
in response to MSC-secreted cytokines, promoting a reduction
programmed cell death (Jiang et al., 2013). Interestingly,
MSCs overexpressing Akt promoted the maintenance of
metabolism, glucose uptake and cytosolic pH and prevention of
cardiac metabolism remodeling in a myocardial infarct model.
Remarkably, for Akt-MSC hearts, systolic performance was only
12% (72 h) to 17% (2 week) lower compared with sham-
operated hearts while diastolic performance remained normal.
In contrast, for unmodified MSC-treated and untreated infarcted
hearts, markers of both systolic and diastolic performance were
significantly lower than for sham-operated hearts (Gnecchi et al.,
2009). Akt-modified amniotic fluid derived MSCs were also
capable of alleviating myocardial injury and contribute to cardiac
regeneration in an ischemia-reperfusion injury in a rabbit model,
promoting angiogenesis by capillary density enhancement and
VEGF expression 2-fold more than control MSCs. Moreover,
Akt-expressing MSCs promoted a significant increase in cTNT,
GATA-4 and connexin 43 compared to controls (Wang et al.,
2016). In addition, purified exosomes from TIMP2- and Akt-
modified umbilical cord MSCs promoted improvements in
cardiac function, by activating TIMP/Akt pathway (Ni et al.,
2019) and increasing platelet-derived growth factor D expression
(Ma et al., 2017), in rats submitted to myocardial infarction.
The expression of CXCR4, the stromal cell-derived factor
(SDF)-1 receptor, which is largely involved in progenitor homing
and survival, has been tested to improve the insufficient cell
homing and tissue persistence observed in several preclinical
studies. CXCR4-MSCs had a 3-fold increase in cell migration
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capacity in vitro and in vivo in a myocardial infarct model
when compared to control MSCs, correlating with an increased
expression of metalloproteinases. Additionally, a 4-fold increase
in capillary density was found in the hearts of animals treated
with CXCR4-MSCs when compared to control MSCs groups
(Huang Z. Y. et al., 2012). A significant improvement in cardiac
function in CXCR4-MSCs treated animals compared to those
treated with control MSCs, which may be explained by the
reduction of heart fibrosis and increased angiogenesis post-injury
(Huang W. et al., 2012; Mayorga et al., 2017; Wu S. Z. et al., 2017).
Furthermore, anti-inflammatory interleukins and regulators
of oxidative factors were explored in the production of
genetically engineered MSCs. IL-10 overexpression improved
the therapeutic effects of MSCs by reducing by 2.5-fold the
production of proinflammatory cytokines (TNF and IL-1β)
and promoting a 3-fold reduction of the heart infarct size
when compared to control MSCs (Meng et al., 2017, 2019).
In addition, injection of MSCs modified to overexpress IL-
33, a cytokine known to induce Th2 and Treg responses
(Schmitz et al., 2005) resulted in a significant improvement of
heart function and reduced inflammation compared to vector
control MSCs in rats with myocardial infarction (Chen et al.,
2019). MSCs modified to overexpress endothelial nitric oxide
synthase (eNOS) were more potent than control MSCs and
eNOS adenoviral vector in reducing the myocardial infarct size
(4 and 2-fold increase, respectively), corrected hemodynamic
parameters and increased the capillary density by increasing
nitric oxide production (Chen L. et al., 2017). Moreover, heme
oxygenase-1 (HO-1), an enzyme acting on heme degradation, as
well as in the generation of cytoprotective agents (Liu and Qian,
2015). Transplantation of HO-1-overexpressing MSCs promoted
not only an improvement in angiogenesis in scar areas, but
also an increase in connexin 43-positive gap junctions and a
higher tyrosine hydroxylase-positive cardiac sympathetic nerves
sprouting in a myocardial infarction model (Zeng et al., 2008,
2010; Yang et al., 2012).
Other molecules with diverse mechanisms of action were
also explored as modification targets were Follistatin-like 1
and Islet-1. MSCs overexpressing Follistatin-like 1, a pro-
survival cardiokine for cardiomyocytes, had increased survival,
proliferation and engraftment, thereby improving in about 2-
fold their therapeutic efficacy when compared to mcherry
transgenic control MSCs in a myocardial infarction model
(Shen et al., 2019). Similarly, overexpression of Islet-1, a
transcription factor involved in cardiogenesis regulation and
a marker of cardiovascular progenitor cells, promoted MSCs
survival post-transplant and enhanced their paracrine function
(Xiang et al., 2018).
Another strategy studied to improve cell therapies for
cardiac diseases is the overexpression of microRNAs in MSCs.
Overexpression of mIR-126 in MSCs induced the production
of Notch ligand Delta-like-4, which activates the Notch
pathway and promotes the production of pro-angiogenic factors,
ameliorating the cell therapy efficacy in infarcted hearts by 2-fold
compared to control MSCs (Huang et al., 2013b). In a similar
way, intramyocardial transplantation of microRNA-1-transfected
MSCs was more effective to promote repair of the infarct injury
and improvement in heart function by enhancing transplanted
cells survival and cardiomyogenic differentiation when compared
to mock-transfected MSCs (Huang et al., 2013a). Furthermore,
in a model of myocardial ischemic-reperfusion injury, mIR-
181a overexpression enhanced the immunosuppressive capacity
of MSCs-derived exosomes, improving their therapeutic effect
by 2 to 3-fold in reducing the infarct area and increasing
the ejection fraction when compared to exosomes produced
by control MSCs (Wei et al., 2019). Genetic modification of
MSCs to overexpress miR-21 not only promoted an enhanced
migration and proliferation rates, but also in angiogenesis
and cardiac function. This may be explained by an increase
in Bcl-2, Cx43 and VEGF levels and a decrease in Bax,
BNP and troponin T, seen in a model of adriamycin-induced
myocardial damage (Zeng et al., 2017). Transplantation of MSCs
overexpressing miR-133 in a rat model of myocardial infarction
reduced fibrosis and promoted an improvement in cardiac
function more potently than control vector-MSCs, possibly by
reducing Snail 1 expression (Chen Y. et al., 2017). Finally,
in a model of myocardial infarction, intravenous injection of
MSCs genetically engineered to overexpress miR-211, known
to influence cell migration, promoted a significant increase
in migration of MSCs to the injured area and reduction
of the infarct size, while PBS or control MSCs did not
reduce the infarct size nor promoted functional recovery
(Hu et al., 2016).
APPLICATIONS IN LUNG DISEASES
Pulmonary tract pathologies are commonly due to the frequent
exposure of the respiratory system to different factors, such as
tobacco, toxic smoke or polluted air, which may contribute to the
development of acute and chronic disorders, such as infections or
autoimmune and inflammatory diseases. Thus, MSCs have been
used and genetically modified to express different factors aiming
to promote the patients’ recovery, since many diseases still do not
have an efficient treatment.
Pulmonary arterial hypertension (PAH) has been a target
of therapies with modified mesenchymal cells. Guo and
collaborators generated rat bone marrow derived MSCs
expressing human HGF (MSC-HGF) by transduction with
recombinant adenoviral vector (ad-HGF). The treatment with
MSC-HGF or MSC-HGF+ recombinant G-CSF promoted a
significant reduction in mean pulmonary arterial pressure and
hypertrophy in the right ventricle when compared with the
control MSCs and untreated groups. In addition, pulmonary
perfusion in the MSC-HGF+G-CSF group was improved by
increasing the number of blood vessels (∼2-fold more vessels
compared with the MSC and untreated group) (Guo et al.,
2013). Treatment with MSCs overexpressing the secreted Klotho
protein (SKL), a β-glucuronidase that regulates oxidative stress
and inflammation, restored pulmonary endothelial dysfunction
in a model of monocrotaline-induced PAH, acting by reducing
25% blood vessel thickness and doubling the lumen when
compared to the MSCs, MSCs-GFP and untreated groups.
MSCs-SKL also slightly attenuated systolic pressure and right
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ventricular hypertrophy and had anti-inflammatory effect,
reducing by 50% the macrophage infiltration in the lung tissue
(Varshney et al., 2016).
In a severe acute lung injury (ALI) mouse model, treatment
with bone marrow-derived MSCs modified to express human
angiopoietin 1 (Ang1) promoted a significant reduction in
airspace inflammation, with 96 % less neutrophils than groups
treated with control MSCs or saline. Moreover, Ang 1-MSCs
reduced the production of pro-inflammatory cytokines IFN-γ,
TNF-α, IL-6 and IL-1β, equal to baseline values observed in naive
mice (Mei et al., 2007). In a similar study, MSCs transduced
by lentiviral vector to overexpress angiopoietin 1 (MSC-Ang1)
also promoted benefits for ALI, reducing the levels of the pro-
inflammatory cytokines TGF-β1 and IL-1β and increasing the
expression of the anti-inflammatory cytokine IL-10 in the serum
and bronchoalveolar lavage fluid, in addition to improving the
lung function by increasing the expression of surfactant protein
C (Shao et al., 2018).
In vitro studies with alveolar epithelial cells subjected
to cigarette smoke extract (CSE) revealed that BMSCs
overexpressing Notch1 receptor (MSC-N1ICD) maintained
alveolar cells proliferation levels close to those observed in the
control not exposed to CSE by activation of PI3K/Akt pathway.
Additionally, MSC-N1ICD doubled the expression of CXCR4,
promoted a 2-fold greater cell migration when compared to the
control MSC groups and prevented apoptosis, as shown by the
50% reduction in caspase-3 expression in alveolar cells when
compared to MSC control cells (Cheng et al., 2017). In another
study, Cai et al. (2015) reported that MSCs genetically modified
to express Wnt/β-catenin contributed in vivo with the alveolar
epithelium protection, promoting the retention of a greater
number of MSCs in the lungs for up to 14 days when compared
to the control cell line, as well as an increase (approximately
3-fold) of differentiation of MSCs in type II alveolar epithelial
cells and improvements in alveolar epithelial permeability,
resulting in a reduction in lung damage.
Mesenchymal stem/stromal cells from different sources have
been genetically modified to express different cytokines and
chemokines in order to explore the immunomodulatory potential
of these cells in lung injury models. The studies demonstrated
that MSCs overexpressing IL-10, CXCR4 or CXCR7 caused
a decrease in the number of alveolar neutrophils and levels
pro-inflammatory cytokines, such as tumor necrosis factor
α (TNFα), transforming growth factor (TGF-β1) and IL-6.
Moreover, an increase in the survival rate of the animals
treated with these genetically modified cells was observed, likely
due to the reduction of inflammatory severity and damage to
the lungs (Wang et al., 2018; Jerkic et al., 2019; Shao et al.,
2019; Zhang C. X. et al., 2019). Differentiation of MSCs into
type II alveolar epithelial cells and an increase of alveolar
macrophages were also observed (Jerkic et al., 2019; Shao et al.,
2019).
Overexpression of enzymes and receptors by MSCs was
another approach used in the management of ALI. In a model of
LPS-induced lung injury, mouse BMSCs modified by a lentiviral
vector to express the angiotensin-converting enzyme 2 (ACE2)
induced an improvement in the lung tissue, with decreased
inflammatory infiltrate, edema and interstitial hemorrhage and
reduction of lung injury score from 13 to 5.7 in WT mice,
and to 8.6 in ACE-knockout mice when compared to the
MSC and untreated groups. In addition, a decrease in IL-6
and IL-1β levels, as well as an increase in IL-10 levels, was
observed in the MSC-ACE2 group compared to the control
MSCs (He et al., 2015). Similarly, Martínez-González et al.
(2013, 2014) observed that human MSCs derived from adipose
tissue overexpressing the soluble IL-1 receptor type 1 (sST2)
caused a decrease in histopathological changes associated with
lower levels of pro-inflammatory cytokines TNF-α, IL-6, and
MIP-2 (1.5 to 3-fold reduction), and 6-fold higher levels of
IL-10 in models of ALI and asthma. In a model of ALI
in rats, BMSCs overexpressing the enzyme heme-oxygenase-
1 (HO-1) promoted the survival and anti-apoptotic activity
greater than wild-type BMSCs (Chen X. et al., 2018). The
transplantation of MSCs overexpressing the type 2 angiotensin
II receptor (AT2R) increased cell migration in vitro by 3-
fold, inhibited inflammation by decreasing pro-inflammatory
cytokines (IL-1β and IL-6) and recovered the injured lung in a
model of ALI in mice (Xu et al., 2018), while overexpression
of the orphan receptor tyrosine kinase 2 (ROR2) by MSCs
not only improved their ability to relieve inflammation and
histopathological changes, but also increased their retention in
lungs (Cai et al., 2016).
Exosomes derived from MSCs are important sources of
microRNAs that provide protection against various diseases.
Therefore, increasing the expression of microRNAs in MSC
is an interesting alternative for some pulmonary pathologies.
In a study that used exosomes derived from MSCs with
overexpression of miR-30b-3p in co-culture with alveolar
epithelial cells (AECs) challenged with type II LPS, high
endocytosis of exosomes rich in miR-30b-3p was found, and
this phenomenon was accompanied by reduced expression
of SAA3 (protein highly expressed in ALI), increased cell
proliferation and inhibition of apoptosis (Yi et al., 2019).
BMSCs overexpressing let-7d, an antifibrotic microRNA, were
tested in an ALI model in mice, promoting an increase in the
production of the anti-inflammatory cytokine IL-1RN (when
compared to wild type MSC), a reduction in the number
of CD45+ cells (when compared to the untreated group)
and decreased collagen transcription levels, even though no
significant differences were observed in the Ashcroft score and
OH-proline (Huleihel et al., 2017). UC-MSCs overexpressing
p130 or E2F4 also proved to be more potent in decreasing
tissue damage in the lungs, promoting retention of MSC-
p130 and MSC-E2F4 7 days after intratracheal transplantation
(50% more retained cells than control groups) and inhibiting
fibrosis in a model of severe acute respiratory distress
(Zhang X. et al., 2019).
Transcription factors are important regulators of gene
expression. The effects of human amniotic MSCs (hAMSCs)
modified to express the nuclear factor erythroid-derived 2-like
2 (Nrf2), a transcription factor that regulates the expression of
genes related to antioxidant activity, was evaluated in a mouse
model of lung injury induced by intratracheal LPS instillation.
Nrf2-overexpressing cells were about 2-fold more potent than
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control MSCs in reducing apoptosis, fibrosis, edema and
pro-inflammatory cytokine levels when injected intravenously
(Zhang et al., 2017).
APPLICATIONS IN GASTROINTESTINAL
AND LIVER DISEASES
Genetic modification of MSCs is a promising approach
widely explored in diverse models of gastrointestinal and
liver diseases. The improvement in cell homing and target
ability to inflammatory sites, together with the increase in
immunosuppression and tissue repair capacity after transplant,
are some of the improvements seen in gastrointestinal
experimental models of oral mucositis and inflammatory
intestinal diseases.
Growth factors have been used as targets for gene therapy in
the field of liver disease, as shown in a study in which HGF-
overexpressing BMSCs (BMSC-HGF) promoted an improved
recovery from liver damage in a model of CCl4-induced cirrhosis
in rats, increasing the expression of hepatic proteins HNF-
4α, CK18 and ALB (2 to 3.5-fold greater than untreated
control) and reducing the presence of liver injury markers,
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), and total bilirubin, compared to the other groups
tested (Zhang Y. et al., 2018). The therapeutic effects of HGF
overexpressing MSCs were also studied in an acute model
of radiation-induced liver injury. MSC-HGF showed greater
migration and permanence in the injured tissue, increased
the proliferation of hepatocytes (about 4-fold greater than
untreated control), completely blocked the increase in ALT
and AST and prevented apoptosis and liver fibrosis when
compared with the other treatments (Zhang J. et al., 2014). In a
similar model of chronic injury, MSCs overexpressing fibroblast
growth factor 4 (FGF4) also contributed with liver regeneration,
promoting greater migration of MSC-FGF4 to cirrhotic livers
and increasing the expression of the liver progenitor marker
EpCAM by about 4-fold when compared to control groups
(Wang et al., 2015).
Hepatic macrophages (Kupffer cells) play a central role in
liver fibrosis, being critical in both its promotion and resolution.
In a model of chronic thioacetamide poisoning (TAA), MSCs
transduced with a lentiviral vector for overexpression of IGF-1
(Ad-MSC-IGF-I) were able to reverse a pro-fibrotic phenotype
in Kupffer cells, reducing by half the levels of collagen
deposition in the area of the lesion when compared to the
vehicle-treated group and downregulating the expression of
the pro-fibrogenic genes TGF-β1, α-SMA and collagen 1A2
(COL1A2) (Fiore et al., 2015). Neuregulin 4 (Nrg4) acts in
the liver, where it modulates the lipogenesis in hepatocytes
by activating the ErbB3/ErbB4 signaling. Thus, the therapeutic
potential of Nrg4-overexpressing Ad-MSCs was tested in
a model of hepatic steatosis induced by a high-fat diet.
Transplantation of MSC-Nrg4 reduced weight gain, decreased
serum glucose and insulin levels, in addition to improving
glucose intolerance more significantly than treatment with
control MSC (Wang W. et al., 2019).
Cytokines and chemokines have also been evaluated in liver
and gastrointestinal diseases. Uncontrolled hepatic immune
activation is the primary pathological mechanism of fulminant
hepatic failure (FHF). The interleukin-1 receptor antagonist (IL-
1Ra) plays an anti-inflammatory and anti-apoptotic role in acute
and chronic inflammation. The transplantation of MSCs that
overexpress this molecule increased survival (63.6% survival in
the MSC-IL-1Ra group versus 30.0% and 22.2% in the MSC
and vehicle groups). MSC-IL-1Ra increased the fraction of
proliferating hepatocytes (23.5%) compared to MSC and control
(19.9% and 18.32%, respectively), and improved liver function
by negatively regulating inflammatory responses activated by
IL-1 in vivo (Zheng et al., 2012). In a TAA-induced model of
chronic liver fibrosis in mice, engineered MSCs that secrete high
levels of IL-10 had a more potent antifibrotic activity and caused
the improvement in liver function than control MSCs, which
were also able to significantly promote histopathological and
functional improvements (Choi et al., 2019).
The role of CXCL2 in oral mucositis was investigated from
transplantation of human BMSCs with increased expression
of CXCR2 by lentiviral transduction. MSC-CXCR2 exhibited
improved ability to migrate in response to CXCL2 in vitro (almost
2 times greater than MSC control), indicating greater targeting
of these cells to the inflamed mucosa in animal models. MSC-
CXCR2 also had a longer residence time in the oral cavity than
control MSC and promoted accelerated ulcer healing by reducing
pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6
and levels of reactive oxygen species (ROS) in epithelial cells
were 2-fold lower, while ROS levels were 4-fold lower in tongue
fibroblasts (Shen et al., 2018). In a mouse model of inflammatory
bowel disease (IBD) induced by sodium dextran sulfate, increased
expression of the Intercellular Adhesion Molecule (ICAM)-1 by
MSCs have been shown to alleviate inflammatory damage in IBD
mice, reducing colon shortening to levels closer to the control
without IBD, in addition to halving the number of inflammatory
cells when compared to the untreated IBD group. Moreover,
ICAM-1 also stimulated the migration of modified MSC to the
affected colon (Li et al., 2019).
In addition, the transfer of genes coding for important
transcription factors regulating hepatogenesis, such as HNF4α
and forkhead box protein (Foxa2), was investigated in the
context of liver diseases in association with stem cell therapy.
MSCs overexpressing Foxa2, cultured in a 3D system of
poly-lactic-co-glycolic acid (PLGA) scaffold, promoted hepatic
differentiation, in vitro and in vivo when implanted into nude
mice. Importantly, when implanted into dorsal subcutaneous
tissues, Foxa2-overexpressing Ad-MSCs/scaffolds reduced the
alterations in liver function markers in the blood and in liver
tissue, in an acute liver injury model induced by TAA (Chae
et al., 2019). Moreover, Foxa2-MSCs promoted the recovery
expressions of liver enzymes close to normal levels, and reduced
the fibrotic areas more potently when compared to MSC alone
or MSC/vector groups (Cho J.W. et al., 2012). Similarly, HNF-
4α-modified MSCs showed increased therapeutic effects in a liver
cirrhosis mouse model, where MSC-HNF-4α positively regulated
iNOS expression by activating the NF-κB signaling pathway
(Ye et al., 2019).
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APPLICATIONS IN KIDNEY DISEASES
Nephrological disorders can lead to an increase in mortality
and morbidity, especially in cases of acute kidney injury, and
may affect the functionality of the organs. The use of genetically
modified MSCs has also been investigated in the context of
kidney diseases.
Ad-MSCs and BMSCs genetically engineered to overexpress
glial cell line-derived neurotrophic factor (GDNF) promoted the
switching of macrophages to a reparative phenotype, reduced
renal fibrosis and contributed to a recovery in renal function in
models of nephrotoxic serum nephritis and unilateral ureteral
obstruction (Huang Z. Y. et al., 2012; Wang Z. et al., 2019). In
another study, injection of MSC-HGF, in a model of bladder
outlet obstruction, not only prevented collagen deposition, with
a reduction in collagen area of almost half when compared to the
untreated animals, as well as increased cystometric parameters
in transplanted animals (Song et al., 2012). In a model of renal
failure-induced anemia, MSC-IGF-1 co-implanted with MSCs
genetically engineered to secrete erythropoietin (MSC-EPO)
promoted a significant hematocrit elevation when compared to
the group which received the MSC-EPO + MSC-null, with a
difference of approximately 20% after 98 days. Additionally, an
improvement in heart function was observed in the animals
treated with MSC-EPO + MSC-IGF-1 (Kucic et al., 2008).
Overexpression of cytokines and chemokines in MSCs
have also been evaluated in models of kidney diseases. In a
model of renal ischemia/reperfusion injury, MSCs genetically
modified to overexpress TGF-β1 increased renal function and
reduced inflammation by a significant decrease in the pro-
inflammatory cytokine expression, such as IL-2, IL-6, and TNF-α,
in comparison to the PBS and MSC groups, and an enhancement
in IL-10 expression of about 2.5-fold when compared to the sham
group (Cai et al., 2019). Lipocalin 2 (Len2), secreted in high levels
into the blood and urine after kidney injury may be an important
cytoprotective agent against injuries caused by oxidative stress
(Roudkenar et al., 2008, 2011). BMSCs overexpressing Len2
prevented cytotoxicity and apoptosis when co-cultured with HK-
2 and HEK293 cells in a model of cisplatin-induced kidney injury
in vitro, with a cell viability of 60% after 70 days when co-
cultured with HK-2 cells and 40% with HEK293 cells, while the
control groups with only kidney cells co-cultured with MSCs
or Mock-MSCs had 20% and less than 10% viability for kidney
cells, respectively. Additionally, the percentage of apoptosis in the
groups treated with MSC-Len2 was significantly decreased, while
HGF, IGF-1 and FGF-2 concentrations were higher in this group
when compared to the other treatments (Halabian et al., 2014).
BMSCs-CXCR4, were also able to stimulate HGF production
when compared to the MSCs alone, although not in the same
intensity as the MSC-Len2. Furthermore, an increase in IL-10
and bone morphogenetic protein 7 (BMP-7) was also observed.
Increasing in proliferating cells and a decrease in apoptotic
cell markers when co-cultured with hypoxia/reoxygenation-
pretreated renal tubular epithelial cells (HR-RTECs), as well as
renal functional improvement and a decrease in tubular cell death
was seen in animals treated with BMSCs-CXCR4 in a model of
acute kidney injury (Liu et al., 2013).
Transplantation of BMSCs modified to express the Klotho
gene, which is known to be related with the aging process (Kuro-
o et al., 1997), promoted antifibrotic effects and led to an increase
in proliferation and immuno-regulatory ability of MSCs in a
model of acute kidney injury (Zhang F. et al., 2018). Moreover,
in a model of ischemia/reperfusion injury, administration of
exosomes derived from BMSCs expressing miR-199a-3p had
protective effects and decreased inflammatory mediators, as well
as the number of apoptotic cells, although this reduction was
similar to the group treated with the MSCs (Zhu et al., 2019).
APPLICATIONS IN NEUROLOGICAL
DISORDERS
Due to the complexity of the nervous system, many neurological
disorders do not have an effective treatment in order to reduce or
prevent the damages caused in the nervous tissue. However, MSC
cell therapy has been investigated as an option for the treatment
of several neurological disorders, and many articles have studied
their effects on the nervous system and possible strategies to
enhance their therapeutic actions, including genetic engineering.
Mesenchymal stem/stromal cells secrete diverse growth
factors related to neurogenesis and neuroprotection, such as
brain derived neurotrophic factor (BDNF), Glial cell-derived
neurotrophic factor (GDNF), fibroblast growth factor-2 (FGF-
2), HGF, IGF-1, nerve growth factor (NGF) and platelet-derived
growth factor (PDGF) (Joyce et al., 2010) and, therefore,
many studies have been evaluating the effects of MSCs
overexpressing these factors for the treatment of neurological
disorders in different in vitro and in vivo models. In a model
of diabetic cistopathy, rats that received intrathecal injections
of human MSCs derived from umbilical cord modified by
lentivirus to overexpress NGF (MSCs-NGF), had a significant
improvement in voiding dysfunction, with a 12% and 45%
voiding interval higher when compared to the MSC control
and untreated diabetic groups, respectively. This effect was
related to the differentiation of MSCs-NGF in neurons and
glial cells, increasing the control of neuronal functions along
the urinary pathway (WenBo et al., 2017). In the in vitro
model of Parkinson’s disease, the conditioned medium MSCs
overexpressing HGF showed an increase in the viability of
neuron culture 48 h after treatment (about 14% greater than
control MSC and 42% greater than untreated cells). In addition,
the presence of intracellular free calcium was 2.4-fold lower
in the MSC-HGF group and about 2-fold lower in the MSC
group when compared to the untreated control, indicating a
greater ability of MSC-HGF to maintain the cellular homeostasis
(Liu et al., 2014). Supernatant of MSCs overexpressing BDNF
from three different donors showed a higher neuroprotective
effect in vitro, with a neuronal survival rate around 40% when
compared to the control-vector infection group (Scheper et al.,
2019), while in another study, MSCs also overexpressing BDNF
started to express neuronal phenotype markers 1 day after
transfection and in the following days, presented a neuron-
like morphology when compared to the MSC control, which
maintained their fibroblast-like morphology (Lim et al., 2011).
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Interestingly, these findings demonstrate that the overexpression
of BDNF by MSCs seems to be able to either increase their
neuroprotective effects or induce changes in their phenotype to
one closer to a neuronal one, suggesting more than one possible
effect in the cells.
In another study, MSCs with GDNF overexpression increased
the differentiation of neural stem cells (NSCs) when these cells
were co-cultured with a 3D microfluidic system. After 5 days
in culture, a significant increase in the expression of neuronal
markers, such as Tuj1 and MAP2, and in the formation of
neurites in NSCs co-cultured with MSC-GDNF when compared
to MSC control group was observed. In addition, the authors
performed an animal model of hypoxic-ischemic stroke to
assess neurobehavioral function. However, even demonstrating
promising effects in vitro, transplantation of MSC-GDNF did
not demonstrate a significant functional increase when compared
to control MSC, being superior only to the untreated group
(Yang et al., 2015). On the other hand, transplantation of MSCs
with increased expression of FGF21 (an important regulator
of metabolic pathways) in the brain of mice after traumatic
brain injury (TBI) led to a decrease in memory deficits and
increased the level of FGF21 in the ipsilateral hippocampus,
naturally decreased after TBI. In addition, the MSC-FGF21
group had enhanced neurogenesis and restored the morphology
of immature newborn neurons in the hippocampus when
compared to the MSC and vehicle groups, which exhibited
impaired maturation and deficiency in the neurogenesis process
(Shahror et al., 2019).
In a model of spinal cord injury (SCI), bone marrow-derived
MSCs overexpressing or not ciliary neurotrophic factor (CNTF)
promoted functional recovery, as shown by an improvement in
the Basso, Beattie, and Bresnahan (BBB) motor score during
the weeks following transplantation, and the H&E staining of
the injury site demonstrated that both groups showed a greater
cell density in the cavity when compared to untreated group.
Nevertheless, even with both cell groups seeming to be able to
preserve the nervous tissue, the BMSC-CNTF group displayed
a profile more similar to the sham group in comparison to
the others (Abbaszadeh et al., 2015). Another study evaluating
the effects of MSCs on SCI showed that transplantation of
MSCs overexpressing HGF reduced the activation of astrocytes
by inhibiting the expression of TGFβ1 and β2, promoting an
almost 3-fold decrease in GFAP+ cells in the lesion area, when
compared to the control or wild type MSCs, in addition to
inducing the reduction of the glial scar, one of the main factors
that hinder the functional recovery after SCI (Jeong et al., 2012).
BMSCs genetically modified to overexpress the growth factor
IGF-1 showed promising effects on neuroprotective and anti-
oxidant activity in mice after SCI. When compared to control
groups, IGF-1 secretion promoted a 3-fold increase in graft
survival in the lesion area, which facilitated the recruitment
of endogenous neural progenitor cells, as well as the positive
regulation of antioxidant genes, resulting better preservation
of neural tissue (myelinated area about 50% greater than that
observed in control groups) and significant motor improvement
using Basso Mouse Scale (BMS; 6 at the end of the experiment
for IGF-1 group vs 4 in control groups) (Allahdadi et al.,
2019). In another SCI model, BMSCs overexpressing sonic
hedgehog (Shh), a growth factor with multiple functions in
the nervous system, were able to reduce tissue damage, with
2 times greater expression of neurofilament 200 (NF200), in
addition to promoting functional recovery significant in animals
when compared to BMSCs or vehicle groups (Jia et al., 2014).
Finally, mice treated with BMSCs genetically modified with
brain dopamine factor (CDNF) showed significant functional
gains in the BBB score, from week 3 to week 6, when
compared to control groups, which did not show significant
differences between themselves. In addition, histopathological
analyzes indicated greater tissue preservation, with a 6 to 7-
fold reduction in the area of cavitary lesions in the MSC-CDNF
group when compared to MSC control and untreated groups.
Neural fiber recovery was also observed, with improvements in
remyelination levels and reduction of neuroinflammation after
SCI (Zhao et al., 2014).
A study evaluating the effects of neurotrophin-3 (NT3)
overexpression by BMSCs in a model of Parkinson’s disease
revealed that genetically modified cells protected neuronal tissue
and induced differentiation of BMSCs into cells similar to
dopaminergic neurons (neuron type affected by Parkinson’s
disease), as seen by a 5-fold increase in the levels of nurr-1 and
wnt-1 in transfected cells, when compared to treatment with
wild-type MSCs (Moradian et al., 2017).
VEGF-overexpressing MSCs have been used in different
disease models, including neurological diseases. In the treatment
of peripheral nerve damage, MSC-VEGF has shown promising
results both in vitro and in vivo, promoting the extension
of neurites and maintaining high expression of VEGF in the
nerves 2 weeks after grafting (Man et al., 2016). In a model of
Alzheimer’s disease, also evaluating the effects of MSC-VEGF,
genetically modified cells promoted neovascularization in the
hippocampus and reduced the presence of beta-amyloid plaques
in the dentate gyrus when compared to the vehicle-treated group,
although no significant differences were found compared to the
MSC group, which also appeared to induce neovascularization
(Garcia et al., 2014).
The immunomodulatory effects of genetically modified MSCs
to express interleukins have been studied to treat autoimmune
diseases, such as multiple sclerosis, or to reduce the damage
caused by trauma to the brain or spinal cord in cases of
TBI, SCI or stroke. Genetically modified MSCs to express IL-
4 (responsible for modulating the autoimmune inflammatory
response), for example, exhibited protective effects in a model
of multiple sclerosis when transplanted in the early stage of the
disease. MSC-IL-4 reduced the expression of pro-inflammatory
cytokines such as IFNγ and IL-6, leading to a reduction
in disease severity when compared to control groups (Payne
et al., 2012). In an acute ischemic stroke model, BMSCs
overexpressing IL-10 ameliorate the motor function, posture
score and forelimb grip strength. In addition, 72 h after
treatment, a decrease in the number of Iba-1 and TNF-α positive
cells, of approximately 2-fold more, was seen in BMSC-IL-
10 group when compared to the vehicle, while this reduction
was of almost half in comparison to the MSC, which also
presented a significant difference in relation to the vehicle group
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(Nakajima et al., 2017). The effects of BMSC-IL-10 were also
evaluated in a TBI model, in which these cells and MSCs alone
decreased significantly the expression of cell death markers, such
as Bax, cytochrome-C, caspase-3 and p53 when compared to
the vehicle group and increase in those related to cell survival
(Bcl2) and synaptic transmission (PSD95 and synaptophysin)
was seen in BMSC-IL-10, but not in MSCs alone and vehicle
groups, which presented differences only in synaptophysin levels.
Thus, these results showed the promising effects of BMSC-
IL-10 in promoting the protection of neuronal cells following
TBI (Maiti et al., 2019). C-C Motif Chemokine Receptor 2
(CCR2) is positively regulated in the first 24 h after ischemic
stroke. Therefore, the effects of MSCs genetically modified
to express CCR2 were evaluated in a stroke model. In this
study, overexpression of CCR2 increased 5-fold approximately
the migration of MSCs modified to ischemic region, and it
was able to not only decrease ischemic injuries and promote
neurological recovery in vivo, but demonstrated an important
role in protecting the blood-brain barrier and in promoting
endothelial regeneration, when compared to the control groups
of MSC (Huang Y. et al., 2018).
Overexpression of enzymes and receptors by MSCs, in order
to improve the protective effects in tissue regeneration or increase
cell survival, has also been studied for the treatment of different
neurological disorders. MSCs derived from different sources
have been genetically modified to express important enzymes
for the CNS. MSCs overexpressing arginine decarboxylase (an
enzyme that regulates the synthesis of agmatine, known to confer
neuroprotection after brain damage) were tested in an SCI model
in rats. Tissue analyzes showed an increase in BDNF expression
at the lesion site, and this effect was accompanied by a reduction
in the area of fibrotic scar and functional improvement in the
group treated with the modified cells. MSCs overexpressing
heme oxygenase-1 (an enzyme that modulates the response to
oxidative stress after spinal cord trauma) were tested in canine
SCI. Overexpression of this molecule led to a functional recovery
after transplantation, related to the anti-oxidative effect and
to a decrease in the presence of infiltrated cells, fibroblast-
like cells and apoptotic cells in the area of the lesion, as
well as an increase in the expression of NeuN and β3-tubulin
markers when compared with the control groups. In addition,
MSCs with increased tropomyosin kinase A (TrkA) receptor, a
receptor highly expressed in sensory fibers, were used to repair
peripheral nerves in rats. 8 weeks after transplantation, the
MSC-TrkA-treated group showed greater axonal growth, with
significantly higher expression of the basic myelin protein and
superior results of the density of myelinated fibers, in addition
to superior functional performance than observed in the control
groups (Park Y.M. et al., 2015; Lee et al., 2017; Zheng et al.,
2017).
In another study, MSCs derived from Wharton’s jelly
genetically modified to express PARKIN (an ubiquitin ligase
capable of protecting dopaminergic neurons against stress)
were tested in the Parkinson’s disease model produced by
6-hydroxydopamine-induced toxicity. The overexpression of
PARKIN in MSCs was able to significantly reduce the expression
of markers of cell death and oxidative stress, in addition to
significantly reducing the production of reactive oxygen species
(∼ 50% reduction) when compared to wild type and control
groups (Bonilla-Porras et al., 2018). Studies in stroke models
showed that MSCs overexpressing extracellular regulating kinase
1/2 or integrin A4 not only were able to show induction of
neuronal differentiation, proliferation of neural stem cells and a
significant functional recovery in mice after the treatment (Gao
et al., 2019), but also demonstrated a significant decrease in
cell aggregation and improvement of cerebral embolism in rats
(Cui et al., 2017).
MicroRNAs have been receiving attention during the past
years due to their involvement in the regulation of different
and important cellular processes (Clark et al., 2014), as shown
in a mouse model of ischemic brain injury, where BMSCs
overexpressing miR-705 contributed to ameliorate neurological
deficits and to suppress neuronal death, associated with a 2-
fold increase in BDNF and VEGF expression when compared to
sham and vehicle groups (Ji et al., 2017). Several studies evaluated
the effects of exosomes derived from genetically modified
MSCs for the treatment of neurological diseases. Exosomes
derived from MSCs overexpressing pigment epithelium-derived
factor (PEDF) or miR-25 showed neuroprotective effects in
models of cerebral ischemia reperfusion and ischemic spinal
cord by mechanisms involved in axonal preservation, such
as regulation of autophagy and apoptosis or reduction of
inflammation and oxidative stress (Huang X. et al., 2018; Zhao
et al., 2018). MSCs overexpressing miR-21, miR-124, or miR-
133b in models of intracerebral hemorrhage, SCI and stroke,
respectively, increased the expression of neuronal markers,
such as β-III tubulin and NF200, induced neurite remodeling
and outgrowth, reduced neurological damages and promoted
functional recovery after treatment (Zou et al., 2014; Xin et al.,
2017; Zhang H. et al., 2018).
Transcription factors have also been expressed by MSCs
for the treatment of neurological diseases. BMSCs genetically
engineered to express hypoxia-inducible factor 1α (HIF-1α) led
to motor functional improvement, decreased cerebral infarction
and increased by 4-fold the VEGF expression, when compared
to the control groups in a model of cerebral artery occlusion
(Yang et al., 2014). In another study, Mash1 overexpressing-
MSCs enhanced neuronal markers expression, such as NeuN
and GAD67, when compared to groups treated with MSCs
control cells. In addition, these cells differentiated into cells
similar to neurons that showed action potential, as seen by
electrophysiological characterization, demonstrating that they
were functional in vitro (Wang K. et al., 2013).
Genetically modified MSCs have also been combined with
other methodologies in order to enhance their effects, as
observed in a SCI model, in which the transplantation of BMSCs
overexpressing BDNF combined with platelet-rich plasma (PRP)
scaffolding promoted an increase in the expression of axonal
markers such as NF200, 4 and 8 weeks after transplantation,
when compared to groups that received control BMSC cells.
Regarding GFAP levels, the BMSC groups, when combined with
PRP, showed an increase in the expression of this molecule
compared to groups without PRP. In addition, a better functional
recovery was observed in the BMSC-BDNF group combined with
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PRP, with a significant gain in the BBB index, when compared
to the control groups (Zhao et al., 2013). Two studies evaluated
the effects of transplanted MSCs genetically engineered to express
tyrosine kinase receptor type 3 (TrkC) in combination with
electroacupuncture (EA) for the treatment of SCI. An increase
in the expression of NT3, an important neurotrophic factor,
was seen in the spinal cord, as well as an improvement in the
functional recovery in the animals which received this combined
therapy. Differentiation of the MSC-TrkC into neuron-like and
oligodendrocyte-like cells was also seen, with an expression of
NF150 and MOSP almost twice as higher when compared to the
control groups. Additionally, a reduction of degenerated myelin
and an increase in the number of remyelinating and normal
myelinated axons either in MSC combined with EA was observed
(Ding et al., 2013, 2015).
CLINICAL TRIALS USING GENETICALLY
MODIFIED MSCS
To date, genetically engineered MSCs are being tested only in
few clinical studies for the treatment of different diseases. Either
by viral or non-viral modification, the clinical use of genetically
modified MSCs raises flags about the safety of cell products and
quality control that should be carefully executed to guarantee the
development of safe and effective alternative treatments.
Application of modified MSCs for genetic diseases treatments
is being explored in the clinical research field in cases of severe
combined immunodeficiency (SCID). The standard therapy for
defective adenosine deaminase (ADA) derived SCID is bone
marrow transplant. However, this procedure involves high risks
and compatible donors are scarce. To overcome these problems,
the collection of hematopoietic stem cells and/or MSCs,
derived from the patient’s bone marrow, followed by lentiviral
transduction to induce correct defective ADA expression and re-
implantation into the patient can be considered as a promising
strategy for SCID treatment. Therefore, safety and efficiency of an
improved self-inactivating lentiviral vector system for therapeutic
gene delivery to patients with SCID, due to a defective ADA gene,
is being studied in an interventional clinical trial (NCT03645460
ClinicalTrials.gov).
Another ongoing example of safety and efficacy evaluation
of a gene transfer phase I/II clinical trial is for treating Fanconi
anemia, a rare, inherited disease that is caused by a gene defect
that primarily affects an individual’s bone marrow, resulting in
decreased production of blood cells. In this trial, autologous
bone marrow derived MSCs and hematopoietic stem cells are
being transduced with a self-inactivating lentiviral vector to
functionally correct the defective gene FANCA. Furthermore,
the effects of an infusion of these modified cells in order to
promote immune reconstitution and long-term correction of
Fanconi anemia associated disease symptoms is being evaluated
(NCT03351868 ClinicalTrials.gov).
In the oncology field, a first clinical trial in solid tumors
was conducted for treatment of advanced gastrointestinal cancer.
Subjects were treated with a combination of genetically modified
autologous bone marrow derived MSCs expressing the herpes
simplex virus thymidine kinase (HSV-TK) (MSC_apceth_101)
and ganciclovir, in order to generate a toxic metabolite for the
tumor cells. In this study, from the 10 patients treated with
this genetically modified MSC, five of them reached a stable
disease and a post-study observation demonstrated a median
overall survival of 15.6 months. In relation to the immunological
markers, a slight increase in baseline levels of IL-6 was seen in 4
of the patients, while 3 demonstrated a slight enhancement in the
levels of this cytokine at the end of the study, when compared to
the baseline. Additionally, a moderate improvement in baseline
levels of IL-8 was seen in 5 patients and 3 of them presented an
increase during the time.
Also an enhancement in TNFα/IL-10 ratio, which suggests a
higher inflammatory effectiveness and an anti-tumor capacity,
was observed in 5 patients as well (von Einem et al., 2019).
In addition, new anticancer immunotherapies are being
developed based on the use of recombinant type I IFNs,
type I IFN-encoding vectors and type I IFN-expressing cells
(Zitvogel et al., 2015). Based on that, a phase I study
evaluating the effects of MSCs secreting IFN-β for ovarian
cancer therapy is ongoing. The study aims to determine the
highest tolerable dose of human MSCs-IFN-β that can be
given to patients with ovarian cancer therapy (NCT02530047
ClinicalTrials.gov). The safety and antitumor activity of a
modified human MSCs are also being studied in a phase I/II
study investigating the outcomes of TRAIL-overexpressing MSCs
in addition to chemotherapy, in metastatic non-small cell lung
cancer (NCT03298763 ClinicalTrials.gov). In another study, the
maximum tolerable dose, safety and efficacy of an intratumoral
injection of the IL-12-expressing Human Mesenchymal Stem
Cell Vaccine GX-051 are being investigated in subjects with
advanced head and neck cancer. IL-12 is a cytokine that induces
the production of IFN-γ, an important anti-tumoral factor.
This study will evaluate the anti-tumor response, as well as
possible changes of IFN-γ and IL-12 levels in blood comparing
to the baseline and changes of immune cell distribution in
tumor tissue after GX-051 intratumoral injection (NCT02079324
ClinicalTrials.gov).
CONCLUSION
The development of genetic engineering technologies and the
continuous improvement in the knowledge of MSCs gene
expression enabled the use of genetically modified MSCs with
enhanced therapeutic properties compared to wild-type MSCs in
a variety of disease models, as discussed in this review. Moreover,
many studies described here showed that genetic modification
of MSCs improved their paracrine effects, protecting viable cells
in a lesion area from further damage and promoting tissue
regeneration and significant functional and behavioral recovery
in many animal models. However, due to issues concerning the
safety and efficacy regarding the use of genetically modified MSCs
for treatments, there is a gap between the experimental models
and clinical trials, and the few clinical studies were conducted or
are being initiated, mainly in the hematology and oncology fields.
Additional preclinical studies are needed to ensure the safety
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and demonstrate the therapeutic potential of engineered MSCs
in more relevant animal models, especially those using medium
or large animal models, giving support to the translation of this
therapeutic modality into a broad variety of clinical settings.
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